Catalog No.
DHJ69202
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Triggering receptor expressed on myeloid cells 2, Triggering receptor expressed on monocytes 2, TREM-2, TREM2
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NZC2
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
AL2p-58
Note
For research use only. Not suitable for clinical or therapeutic use.
Microglia at sites of atrophy restrict the progression of retinal degeneration via galectin-3 and Trem2., PMID:38289348
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma., PMID:38372949
sTREM2 Differentially Affects Cytokine Expression in Myeloid-Derived Cell Models via MAPK-JNK Signaling Pathway., PMID:38392305
Modulation of hippocampal protein expression by a brain penetrant biologic TNF-α inhibitor in the 3xTg Alzheimer's disease mice., PMID:38500108
Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability-Brief Report., PMID:38695172
Microglia, Trem2, and Neurodegeneration., PMID:38769824
Distinct roles of TREM2 in central nervous system cancers and peripheral cancers., PMID:38788719
Mapping Endothelial-Macrophage Interactions in Diabetic Vasculature: Role of TREM2 in Vascular Inflammation and Ischemic Response., PMID:38798611
Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer's Disease and Multiple Sclerosis., PMID:38830764
Involvement of Siglec-15 in regulating RAP1/RAC signaling in cytoskeletal remodeling in osteoclasts mediated by macrophage colony-stimulating factor., PMID:38849345
Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma., PMID:38948071
Multimerization of TREM2 is impaired by Alzheimer's disease-associated variants., PMID:39032157
Associations between Microglia and Astrocytic Proteins and Tau Biomarkers across the Continuum of Alzheimer's Disease., PMID:39062786
Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?, PMID:39080712
Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonism., PMID:39090679
Therapeutic Spp1 silencing in TREM2+ cardiac macrophages suppresses atrial fibrillation., PMID:39149373
Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer's disease., PMID:39177331
Phagocytosis Checkpoints in Glioblastoma: CD47 and Beyond., PMID:39194679
Rapid affinity optimization of an anti-TREM2 clinical lead antibody by cross-lineage immune repertoire mining., PMID:39333507
Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model., PMID:39353433
PET imaging of microglia in Alzheimer's disease using copper-64 labeled TREM2 antibodies., PMID:39431020
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer's disease., PMID:39434125
Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease., PMID:39444037
Targeting TREM2 signaling shows limited impact on cerebrovascular calcification., PMID:39467636
Soluble TREM2 distinguishes neuromyelitis optica spectrum disorder from MOG antibody disease., PMID:39530260
Inflammatory crosstalk impairs phagocytic receptors and aggravates atherosclerosis in clonal hematopoiesis in mice., PMID:39531316
Roles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer's Disease., PMID:39559879
The Challenges of Modulating Neuroinflammation in Alzheimer's Disease and Multiple Sclerosis with TREM2 Agonistic Antibodies., PMID:39663111
Soluble TREM2 drives triple-negative breast cancer progression via activation of the AKT pathway., PMID:39672020
Exosomes derived from TREM-2 knocked-out macrophages alleviated renal fibrosis via HSPa1b/AKT pathway., PMID:39657110
A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology., PMID:39676023
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma., PMID:39709141
Rescue of in vitro models of CSF1R-related adult-onset leukodystrophy by iluzanebart: mechanisms and therapeutic implications of TREM2 agonism., PMID:39891235
TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity., PMID:39971937
Biological signatures in the Alzheimer's continuum discriminate between diagnosis-related and -unrelated associations to ATN categories., PMID:40046342
Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer's disease., PMID:40050704
Pro-Fibrotic Macrophage Subtypes: SPP1+ Macrophages as a Key Player and Therapeutic Target in Cardiac Fibrosis?, PMID:40072075
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer., PMID:40081941
IL-33-Induced TREM2+ Macrophages Promote Pathological New Bone Formation Through CREG1-IGF2R Axis in Ankylosing Spondylitis., PMID:40091508
TREM2 scFv-Engineering Escherichia coli Displaying Modulation of Macrophages to Boost Cancer Radio-Immunotherapy., PMID:40103438
Acute TREM2 inhibition depletes MAFB-high microglia and hinders remyelination., PMID:40131948
Antibody-induced TREM2 ectodomain shedding inhibits TREM2 signaling in macrophage., PMID:40138757
Choroidal Neovascularization Is Suppressed With Activation of TREM2 in Mononuclear Phagocytes-Brief Report., PMID:40143815
Phase 1, First-In-Human, Single-/Multiple-Ascending Dose Study of Iluzanebart in Healthy Volunteers., PMID:40166927
The potential and challenges of TREM2-targeted therapy in Alzheimer's disease: insights from the INVOKE-2 study., PMID:40353063
Novel fully human high-affinity anti-TREM2 antibody shows efficacy in clinically relevant Alzheimer´s mouse model., PMID:40405265
Targeted Reprogramming of TREM2-Positive Macrophages and MRI-Guided Immune Monitoring in Colorectal Cancer Using CSF1R@Mn@MPDA-Antitrem2 Nanoplatform., PMID:40417930
PET imaging of TREM2 in amyloid-beta induced neuroinflammation., PMID:40434494
Trem2 regulates microglial migratory responses via type I interferon signaling during photoreceptor degeneration., PMID:40468324
TREM2 Hit Discovery Using TRIC Technology: A Proof-of-Concept High-Throughput Screening Approach., PMID:40501992
For research use only. Not for human or drug use.
